RS63104B1 - Sastavi za ubrizgavanje koji sadrže letrozol ili anastrozol - Google Patents

Sastavi za ubrizgavanje koji sadrže letrozol ili anastrozol

Info

Publication number
RS63104B1
RS63104B1 RS20220307A RSP20220307A RS63104B1 RS 63104 B1 RS63104 B1 RS 63104B1 RS 20220307 A RS20220307 A RS 20220307A RS P20220307 A RSP20220307 A RS P20220307A RS 63104 B1 RS63104 B1 RS 63104B1
Authority
RS
Serbia
Prior art keywords
dmso
composition
situ
pla
aromatase inhibitor
Prior art date
Application number
RS20220307A
Other languages
English (en)
Serbian (sr)
Inventor
Rodríguez Guillermo Franco
Aduriz Ibon Gutierro
Original Assignee
Laboratorios Farmaceuticos Rovi S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47046938&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS63104(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratorios Farmaceuticos Rovi S A filed Critical Laboratorios Farmaceuticos Rovi S A
Publication of RS63104B1 publication Critical patent/RS63104B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RS20220307A 2012-08-03 2013-07-29 Sastavi za ubrizgavanje koji sadrže letrozol ili anastrozol RS63104B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES201231271A ES2390439B1 (es) 2012-08-03 2012-08-03 Composición inyectable
EP13742226.7A EP2879661B1 (en) 2012-08-03 2013-07-29 Injectable compositions comprising letrozole or anastrozole
PCT/EP2013/065877 WO2014019972A1 (en) 2012-08-03 2013-07-29 Injectable compositions comprising letrozole or anastrozole

Publications (1)

Publication Number Publication Date
RS63104B1 true RS63104B1 (sr) 2022-04-29

Family

ID=47046938

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20220307A RS63104B1 (sr) 2012-08-03 2013-07-29 Sastavi za ubrizgavanje koji sadrže letrozol ili anastrozol

Country Status (31)

Country Link
EP (1) EP2879661B1 (forum.php)
JP (1) JP6317348B2 (forum.php)
KR (1) KR101892109B1 (forum.php)
CN (1) CN104519870B (forum.php)
AU (1) AU2013298705B2 (forum.php)
BR (1) BR112015002370B1 (forum.php)
CA (1) CA2880347C (forum.php)
CL (1) CL2015000259A1 (forum.php)
CY (1) CY1125157T1 (forum.php)
DK (1) DK2879661T3 (forum.php)
EA (1) EA033316B1 (forum.php)
ES (2) ES2390439B1 (forum.php)
HR (1) HRP20220537T1 (forum.php)
HU (1) HUE058322T2 (forum.php)
IL (1) IL236981B (forum.php)
IN (1) IN2015DN01711A (forum.php)
LT (1) LT2879661T (forum.php)
MA (1) MA37870B1 (forum.php)
MX (1) MX362874B (forum.php)
MY (1) MY194726A (forum.php)
NZ (1) NZ705558A (forum.php)
PH (1) PH12015500231B1 (forum.php)
PL (1) PL2879661T3 (forum.php)
PT (1) PT2879661T (forum.php)
RS (1) RS63104B1 (forum.php)
SG (1) SG11201500793VA (forum.php)
SI (1) SI2879661T1 (forum.php)
SM (1) SMT202200127T1 (forum.php)
UA (1) UA113317C2 (forum.php)
WO (1) WO2014019972A1 (forum.php)
ZA (1) ZA201501426B (forum.php)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
EP2394663B1 (en) 2010-05-31 2021-10-13 Laboratorios Farmaceuticos Rovi, S.A. Compositions for injectable in-situ biodegradable implants
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
PE20210047A1 (es) * 2018-06-12 2021-01-08 Farm Rovi Lab Sa Composicion inyectable
EP4041189B1 (en) * 2019-10-07 2025-09-17 Oak Crest Institute of Science Orally implantable drug delivery device
KR102319352B1 (ko) 2021-02-03 2021-10-29 바이오메디팜 어업회사법인 주식회사 첨연어의 수컷화 비율을 높이는 비호르몬적 방법
US12318387B2 (en) 2021-07-16 2025-06-03 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
WO2025153747A1 (es) * 2024-01-17 2025-07-24 Laboratorios Farmacéuticos Rovi, S.A. Composiciones y esquemas de dosificación de inhibidores de aromatasa mejorados

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
GB0517674D0 (en) * 2005-08-31 2005-10-05 Astrazeneca Ab Formulation
GB0517673D0 (en) 2005-08-31 2005-10-05 Astrazeneca Ab Formulation
KR20090087441A (ko) 2006-10-05 2009-08-17 파나세아 바이오테크 리미티드 새로운 형태의 주입형 데포 조성물 및 이를 위한 조제방법
CL2008003305A1 (es) * 2007-11-06 2009-06-05 M/S Panacea Biotec Ltd Composicion inyectable que comprende un agente activo seleccionado de un grupo definido; al menos un polimero bioerosionable, al menos un solvente no toxico y opcionalmente uno o mas excipientes; proceso de preparacion; uso para tratar enfermedades mentales o cancer.
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US20100144687A1 (en) 2008-12-05 2010-06-10 Glaser Rebecca L Pharmaceutical compositions containing testosterone and an aromatase inhibitor
EP2394663B1 (en) * 2010-05-31 2021-10-13 Laboratorios Farmaceuticos Rovi, S.A. Compositions for injectable in-situ biodegradable implants
EA026964B1 (ru) 2010-11-24 2017-06-30 Дьюрект Корпорейшн Биоразлагаемая композиция для доставки лекарственного средства (варианты)

Also Published As

Publication number Publication date
BR112015002370A2 (pt) 2017-07-04
CA2880347A1 (en) 2014-02-06
JP2015523405A (ja) 2015-08-13
CA2880347C (en) 2021-05-04
MX362874B (es) 2019-02-20
LT2879661T (lt) 2022-04-11
IL236981B (en) 2021-12-01
MA37870A1 (fr) 2016-04-29
PH12015500231A1 (en) 2015-04-06
IL236981A0 (en) 2015-03-31
AU2013298705A1 (en) 2015-03-12
IN2015DN01711A (forum.php) 2015-05-22
WO2014019972A1 (en) 2014-02-06
CN104519870B (zh) 2017-09-15
CL2015000259A1 (es) 2015-06-05
PH12015500231B1 (en) 2015-04-06
NZ705558A (en) 2018-02-23
PT2879661T (pt) 2022-04-06
JP6317348B2 (ja) 2018-04-25
UA113317C2 (xx) 2017-01-10
ES2926715T3 (es) 2022-10-27
HUE058322T2 (hu) 2022-07-28
ZA201501426B (en) 2016-01-27
SMT202200127T1 (it) 2022-07-21
BR112015002370B1 (pt) 2023-04-25
AU2013298705B2 (en) 2018-03-08
CN104519870A (zh) 2015-04-15
ES2390439B1 (es) 2013-09-27
PL2879661T3 (pl) 2022-05-16
KR101892109B1 (ko) 2018-09-28
EA033316B1 (ru) 2019-09-30
HK1204551A1 (en) 2015-11-27
KR20150040337A (ko) 2015-04-14
ES2390439A1 (es) 2012-11-13
EP2879661A1 (en) 2015-06-10
MY194726A (en) 2022-12-15
EP2879661B1 (en) 2022-01-26
MA37870B1 (fr) 2017-01-31
HRP20220537T1 (hr) 2022-06-10
CY1125157T1 (el) 2024-02-16
MX2015001513A (es) 2015-04-08
SI2879661T1 (sl) 2022-07-29
DK2879661T3 (da) 2022-04-19
SG11201500793VA (en) 2015-02-27
EA201500196A1 (ru) 2015-05-29

Similar Documents

Publication Publication Date Title
RS63104B1 (sr) Sastavi za ubrizgavanje koji sadrže letrozol ili anastrozol
US11918682B2 (en) Injectable composition with aromatase inhibitor
KR101892496B1 (ko) 팔리페리돈 임플란트 제형
RS55190B1 (sr) Antipsihotička injektabilna deponujuća kompozicija
RS53205B (sr) Formulacija implantabilnog paliperidona
Wang et al. Parenteral thermo-sensitive organogel for schizophrenia therapy, in vitro and in vivo evaluation
JP7752051B2 (ja) 長時間作用型注射用製剤およびその使用
TR201809874T4 (tr) Somatostati̇n analoglarinin sürekli̇ salimi i̇çi̇n farmasöti̇k bi̇leşi̇mleri̇n hazirlanmasi süreci̇.
Cespi et al. Evaluation of thermosensitive poloxamer 407 gel systems for the sustained release of estradiol in a fish model
CN108143715A (zh) 一种氟比洛芬酯注射液
RS62681B1 (sr) Injektabilni sastav
WO2016036588A1 (en) Pharmaceutical suspensions containing etoricoxib
CN106377498B (zh) 含三乙酸甘油酯、苯甲酸苄酯和蓖麻油的抗寄生虫注射剂
HK1204551B (en) Injectable compositions
CN118804749B (zh) 用于治疗疼痛的药物组合物
Negi et al. Design and Analysis of an Emulgel Including Microcapsules of Etoricoxib
WO2024168024A1 (en) Degarelix organic solvent formulations
JP2024516264A (ja) 新規製剤
WO2021058651A1 (en) Hydrogel compositions for the controlled and constant release of active agents
Chantadee et al. Vancomycin hydrochloride-loaded stearic acid/lauric acid in situ